NZ714092B2 - Intravascular delivery of nanoparticle compositions and uses thereof - Google Patents
Intravascular delivery of nanoparticle compositions and uses thereof Download PDFInfo
- Publication number
- NZ714092B2 NZ714092B2 NZ714092A NZ71409212A NZ714092B2 NZ 714092 B2 NZ714092 B2 NZ 714092B2 NZ 714092 A NZ714092 A NZ 714092A NZ 71409212 A NZ71409212 A NZ 71409212A NZ 714092 B2 NZ714092 B2 NZ 714092B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- blood vessel
- composition
- albumin
- nanoparticles
- macrolide
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 301
- 239000000203 mixture Substances 0.000 title claims abstract description 289
- 210000004204 Blood Vessels Anatomy 0.000 claims abstract description 255
- 102100001249 ALB Human genes 0.000 claims abstract description 154
- 101710027066 ALB Proteins 0.000 claims abstract description 154
- 229940050528 albumin Drugs 0.000 claims abstract description 153
- 239000003120 macrolide antibiotic agent Substances 0.000 claims abstract description 150
- 229960002930 sirolimus Drugs 0.000 claims abstract description 98
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 90
- 210000001519 tissues Anatomy 0.000 claims abstract description 84
- 239000003814 drug Substances 0.000 claims abstract description 27
- 200000000008 restenosis Diseases 0.000 claims abstract description 13
- 206010002383 Angina pectoris Diseases 0.000 claims abstract description 12
- 206010022562 Intermittent claudication Diseases 0.000 claims abstract description 12
- 206010003119 Arrhythmia Diseases 0.000 claims abstract description 11
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims abstract description 11
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 11
- 208000010125 Myocardial Infarction Diseases 0.000 claims abstract description 11
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims abstract description 11
- 230000001684 chronic Effects 0.000 claims abstract description 11
- 201000006233 congestive heart failure Diseases 0.000 claims abstract description 11
- 201000002818 limb ischemia Diseases 0.000 claims abstract description 11
- 201000002911 peripheral artery disease Diseases 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims description 60
- 238000002347 injection Methods 0.000 claims description 59
- 201000010099 disease Diseases 0.000 claims description 56
- 210000001367 Arteries Anatomy 0.000 claims description 48
- 230000002792 vascular Effects 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 22
- 210000002808 Connective Tissue Anatomy 0.000 claims description 21
- 210000003462 Veins Anatomy 0.000 claims description 20
- 238000002399 angioplasty Methods 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 210000004351 Coronary Vessels Anatomy 0.000 claims description 6
- 210000001147 Pulmonary Artery Anatomy 0.000 claims description 5
- 230000002093 peripheral Effects 0.000 claims description 5
- 210000002254 Renal Artery Anatomy 0.000 claims description 4
- 210000001627 Cerebral Arteries Anatomy 0.000 claims description 3
- 108091006822 Human Serum Albumin Proteins 0.000 abstract description 57
- 102000008100 Human Serum Albumin Human genes 0.000 abstract description 57
- 206010016654 Fibrosis Diseases 0.000 description 42
- 230000004761 fibrosis Effects 0.000 description 42
- 238000007634 remodeling Methods 0.000 description 38
- 210000001105 Femoral Artery Anatomy 0.000 description 30
- 239000002245 particle Substances 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 20
- 239000002609 media Substances 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 231100000486 side effect Toxicity 0.000 description 12
- 200000000009 stenosis Diseases 0.000 description 12
- 230000036262 stenosis Effects 0.000 description 12
- -1 human serum albumin) Chemical compound 0.000 description 11
- 210000000265 Leukocytes Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000001737 promoting Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000008389 polyethoxylated castor oil Substances 0.000 description 6
- 206010022114 Injury Diseases 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000003038 Endothelium Anatomy 0.000 description 4
- 210000002744 Extracellular Matrix Anatomy 0.000 description 4
- 229940041033 Macrolides Drugs 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003902 lesions Effects 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000651 myofibroblasts Anatomy 0.000 description 4
- 230000036231 pharmacokinetics Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 3
- 210000002469 Basement Membrane Anatomy 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010020718 Hyperplasia Diseases 0.000 description 3
- 210000003090 Iliac Artery Anatomy 0.000 description 3
- 210000003111 Iliac Vein Anatomy 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 229940067631 Phospholipids Drugs 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 210000003752 Saphenous Vein Anatomy 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010002906 Aortic stenosis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 210000001715 Carotid Arteries Anatomy 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 210000003191 Femoral Vein Anatomy 0.000 description 2
- 210000003127 Knee Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 210000002414 Leg Anatomy 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 210000001758 Mesenteric Veins Anatomy 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000003492 Pulmonary Veins Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000002465 Tibial Arteries Anatomy 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 210000004231 Tunica Media Anatomy 0.000 description 2
- SNKAWJBJQDLSFF-YEUCEMRASA-N [2-({2,3-bis[(9Z)-octadec-9-enoyloxy]propyl phosphonato}oxy)ethyl]trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-YEUCEMRASA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 201000008739 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001815 facial Effects 0.000 description 2
- 238000009459 flexible packaging Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000002608 intravascular ultrasound Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001872 metatarsal bones Anatomy 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-M 2-carboxy-6-propylphenolate Chemical class CCCC1=CC=CC(C([O-])=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-M 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 210000000702 Aorta, Abdominal Anatomy 0.000 description 1
- 208000004670 Arteriolosclerosis Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 229940085334 Aspirin 81 MG Drugs 0.000 description 1
- 210000004191 Axillary Artery Anatomy 0.000 description 1
- 210000002048 Axillary Vein Anatomy 0.000 description 1
- 229940093761 Bile Salts Drugs 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000002302 Brachial Artery Anatomy 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 210000000269 Carotid Artery, External Anatomy 0.000 description 1
- 208000006170 Carotid Stenosis Diseases 0.000 description 1
- 206010007687 Carotid artery stenosis Diseases 0.000 description 1
- 210000002434 Celiac Artery Anatomy 0.000 description 1
- 229960001091 Chenodeoxycholic Acid Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N Chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229960002997 Dehydrocholic Acid Drugs 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N Dehydrocholic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 210000002969 Egg Yolk Anatomy 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 1
- 229940099347 Glycocholic Acid Drugs 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 210000002767 Hepatic Artery Anatomy 0.000 description 1
- 210000002989 Hepatic Veins Anatomy 0.000 description 1
- 210000004276 Hyalin Anatomy 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 210000004731 Jugular Veins Anatomy 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N Lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 210000004249 Mesenteric Artery, Inferior Anatomy 0.000 description 1
- 210000001363 Mesenteric Artery, Superior Anatomy 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- 208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- JLPULHDHAOZNQI-GSZNELEDSA-N Palmitoyl-Linoleoyl Phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-GSZNELEDSA-N 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010072563 Peripheral artery stenosis Diseases 0.000 description 1
- 206010034606 Peripheral neuropathy Diseases 0.000 description 1
- 208000001297 Phlebitis Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 210000003137 Popliteal Artery Anatomy 0.000 description 1
- 210000003240 Portal Vein Anatomy 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N Propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 208000009138 Pulmonary Valve Stenosis Diseases 0.000 description 1
- 210000002321 Radial Artery Anatomy 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- 210000002796 Renal Veins Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 210000002563 Splenic Artery Anatomy 0.000 description 1
- 210000000955 Splenic Vein Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000003270 Subclavian Artery Anatomy 0.000 description 1
- 210000001321 Subclavian Vein Anatomy 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N Taurocholic Acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044642 Tricuspid valve stenosis Diseases 0.000 description 1
- 210000004026 Tunica Intima Anatomy 0.000 description 1
- 210000002559 Ulnar Artery Anatomy 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N Ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 Ursodiol Drugs 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 210000001604 Vasa Vasorum Anatomy 0.000 description 1
- 210000001631 Vena Cava, Inferior Anatomy 0.000 description 1
- 210000002620 Vena Cava, Superior Anatomy 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 201000002936 artery disease Diseases 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 229950001904 chenodiol Drugs 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000002016 colloidosmotic Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- RYPWQHONZWFXBN-UHFFFAOYSA-N dichloromethyl(methylidene)-$l^{3}-chlorane Chemical compound ClC(Cl)Cl=C RYPWQHONZWFXBN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 1
- CITHEXJVPOWHKC-UHFFFAOYSA-N dimyristoylphosphatidyl choline Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002146 exchange transfusion Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 102000034327 globular proteins Human genes 0.000 description 1
- 108091005889 globular proteins Proteins 0.000 description 1
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 230000002390 hyperplastic Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006346 neonatal jaundice Diseases 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000006351 renal artery disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229940080274 sodium cholesteryl sulfate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 229940115889 ursodeoxycholic acid Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
- A61M2025/0089—Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Provided is the use of a composition comprising nanoparticles comprising a macrolide and an albumin in the manufacture of a medicament for treating angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, peripheral artery disease, claudication, chronic limb ischemia or restenosis, wherein the medicament is to be injected into a blood vessel wall or tissue surrounding the blood vessel wall. The macrolide may be rapamycin. The albumin may be human serum albumin. s, wherein the medicament is to be injected into a blood vessel wall or tissue surrounding the blood vessel wall. The macrolide may be rapamycin. The albumin may be human serum albumin.
Description
INTRAVASCULAR DELIVERY OF NANOPARTICLE COMPOSITIONS AND USES
THEREOF
RELATED APPLICATIONS
This is a divisional application of New Zealand patent application NZ 617139
dated 27 April 2012. This application claims priority benefit of U.S. Provisional Application
Serial No. 61/518,084, filed April 28, 2011 and U.S. Provisional Application Serial No.
61/557,851, filed November 9, 2011, the contents of each are incorporated herein in their
entirety.
TECHNICAL FIELD
The present invention relates to methods of delivering and use of a composition
comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the
nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel
wall.
BACKGROUND
Coronary artery disease is one of the leading causes of death throughout the
world. While coronary artery bypass surgery is an effective treatment for stenosed arteries
resulting from atherosclerosis and other causes, it is a highly invasive procedure and requires
substantial hospital and recovery time. Percutaneous transluminal coronary angioplasty (PTCA),
commonly referred to as balloon angioplasty, is less invasive, less traumatic, and significantly
less expensive than bypass surgery. The effectiveness of balloon angioplasty has improved
significantly with the introduction of stenting which involves the placement of a scaffold
structure within the artery which has been treated by balloon angioplasty. The stent inhibits
abrupt reclosure of the artery and has some benefit in reducing subsequent restenosis resulting
from hyperplasia. Despite such improvement, patients who have undergone angioplasty
procedures with subsequent stenting still suffer from a high incidence of restenosis resulting
from hyperplasia. Implanting of stents which have been coated with anti-proliferative drugs can
significantly reduce the occurrence of hyperplasia.
Albumin-based nanoparticle compositions have been developed as a drug
delivery system for delivering substantially water insoluble drugs such as a taxanes. See, for
example, U.S. Pat. Nos. 5,916,596; 6,506,405; 6,749,868, and 6,537,579, 7,820,788, and
7,923,536. It is generally believed that the albumin-based nanoparticle, such as Abraxane®,
when introduced into the blood stream, would dissolve into albumin-drug complexes. Such
complexes utilize the natural properties of the protein albumin to transport and deliver
substantially water insoluble drugs to the site of disease, such as tumor sites. In addition, the
albumin-based nanoparticle technology offers the ability to improve a drug’s solubility by
avoiding the need for toxic chemicals, such as solvents, in the administration process, thus
potentially improving safety through the elimination of solvent-related side effects.
The disclosures of all publications, patents, patent applications and published
patent applications referred to herein are hereby incorporated herein by reference in their
entirety.
BRIEF SUMMARY OF THE INVENTION
[0005a] In a first embodiment, the invention provides a use of a composition comprising
nanoparticles comprising a macrolide and an albumin in the manufacture of a medicament for
treating a disease selected from the group consisting of angina, myocardial infarction, congestive
heart failure, cardiac arrhythmia, peripheral artery disease, claudication, and chronic limb
ischemia in an individual in need thereof, wherein the medicament is to be injected into a blood
vessel wall or tissue surrounding the blood vessel wall in the individual.
[0005b] In a second embodiment, the invention provides a use of a composition
comprising nanoparticles comprising a macrolide and an albumin in the manufacture of a
medicament for treating restenosis in a blood vessel in an individual in need thereof, wherein the
medicament is to be injected into the blood vessel wall or tissue surrounding the blood vessel
wall.
Also described is a method of delivering a composition comprising nanoparticles
comprising albumin and a macrolide to a blood vessel, wherein the method comprises injecting
into the blood vessel wall or tissue surrounding the blood vessel wall an effective amount of a
composition comprising nanoparticles comprising a macrolide and an albumin. Also described is
a method of inhibiting negative remodeling in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising a macrolide and an
albumin. Also described is a method of inhibiting vascular fibrosis (such as medial fibrosis or
adventitia fibrosis) in a blood vessel in an individual in need thereof, comprising injecting into
the blood vessel wall or tissue surrounding the blood vessel wall an effective amount of a
composition comprising nanoparticles comprising a macrolide and an albumin. Also described
is a method of reducing proliferation index in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising a macrolide and an
albumin. In some embodiments, there is provided a method of promoting positive remodeling in
a blood vessel in an individual in need thereof, comprising injecting into the blood vessel wall or
tissue surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin.
In some embodiments, the blood vessel is an artery, such as a coronary artery or a
peripheral artery. In some embodiments, the artery is selected from the group consisting of renal
artery, cerebral artery, pulmonary artery, and artery in the leg. In some embodiments, the blood
vessel is a vein.
In some embodiments, the nanoparticle composition is injected into the blood
vessel wall. In some embodiments, the nanoparticle composition is injected into the tissue
surrounding the blood vessel wall. In some embodiments, the nanoparticle composition is
injected into the adventitial tissue of the blood vessel.
In some embodiments, the nanoparticle composition is injected at a dose of about
0.001 mg to about 100 mg, including for example about 0.05 mg to about 5 mg. In some
embodiments, the injection volume of the nanoparticle composition is about 0.01ml to about 50
ml, including for example, about 0.5 ml to about 5 ml. In some embodiments, the nanoparticle
composition is injected though a catheter with a needle, such as a deployable needle. In some
embodiments, the nanoparticle composition is injected at least once a year. In some
embodiments, the nanoparticle composition is injected only once.
In some embodiments, the nanoparticle composition is injected distal to the
disease site. In some embodiments, the nanoparticle composition is injected proximal to the
disease site. In some embodiments, the nanoparticle composition is injected at or adjacent to
the disease site. In some embodiments, the nanoparticle composition is injected remotely from
the disease site. In some embodiments, the nanoparticle composition is injected at least about 2
cm (including for example at least any of 3, 4, 5, 6, 7, 8, 9, or 10 cm) away from the disease site.
In some embodiment according to any of the above embodiments, the individual
has any one of: angina, myocardial infarction, congestive heart failure, cardiac arrhythmia,
peripheral artery disease, claudication, or chronic limb ischemia. In some embodiments, the
individual is a human. In some embodiments, the method is carried out during vascular
interventional procedure, including but not limited to, angioplasty (such as percutaneous
translumenal coronary angioplasty), stenting, or atherectomy. In some embodiments, the
method is carried out after a vascular interventional procedure, including but not limited to,
angioplasty, stenting, or atherectomy.
In some embodiments according to any of the above embodiments, the macrolide
is rapamycin or a derivative thereof. In some embodiments, the macrolide is rapamycin. In
some embodiments according to any of the above embodiments, the nanoparticles in the
composition have an average diameter of no greater than about 200 nm, such as no greater than
about 100 nm. In some embodiments, the nanoparticles in the composition have an average
diameter of no less than about 70 nm. In some embodiments, the macrolide in the nanoparticles
is coated with albumin.
Also described are kits and devices for use in any of the methods described
herein. For example, in some embodiments, there is provided a catheter with a needle (such as a
deployable needle), wherein the needle contains a composition comprising nanoparticles
comprising a macrolide and an albumin. In some embodiments, the macrolide is rapamycin. In
some embodiments, the nanoparticles comprise a macrolide coated with albumin. In some
embodiments, the nanoparticles in the composition have an average diameter of no greater than
about 200 nm, such as no greater than about 100 nm. In some embodiments, the nanoparticles in
the composition have an average diameter of no less than about 70 nm.
These and other aspects and advantages of the present invention will become
apparent from the subsequent detailed description and the appended claims. It is to be
understood that one, some, or all of the properties of the various embodiments described herein
may be combined to form other embodiments of the present invention.
BRIEF DESCRIPTION OF FIGURES
Figure 1 provides images of the micro-infusion catheter utilized for
periadventitial injection of Nab-rapamycin in the femoral artery. Figure 1A shows a deflated
balloon which sheathes the needle. Figure 1B shows an inflated balloon with the needle
extruding outward.
Figure 2 provides two flow charts for the study design involving periadventitial
injection of Nab-rapamycin in a porcine femoral artery balloon angioplasty injury model. Figure
2A shows a flow chart for pharmacokinetics studies. Figure 2B shows a flow chart for
histopathology studies.
Figures 3A-F show a representative angiogram series for periadventitial injection
of Nab-rapamycin in the femoral artery.
Figures 4A-4D show reduction of luminal stenosis after periadventitial delivery
of Nab-rapamycin as measured by mean lumen cross-sectional area (4A), mean artery cross
sectional area (4B), mean percent luminal stenosis (4C), and average medial fibrosis (4D).
Figures 5A and 5B show the pharmacokinetics of Nab-rapamycin after
periadventitial delivery in femoral arteries as measured by serum rapamycin concentration (5A)
and tissue rapamycin concentration (5B).
Figures 6A-6D show histopathology staining of femoral arteries treated with (6C
and 6D) or with (6A and 6B) Nab-rapamycin by periadventitial delivery. Figures 6A and 6C
show staining with H&E. Figures 6B and 6D show staining with trichrome.
Figure 7A shows the proliferative index after periadventitial delivery of Nab-
rapamycin or a control. Figure 7B shows the endothelialization after periadventitial delivery of
Nab-rapamycin or a control.
Figure 8A shows the proliferative index after periadventitial delivery of Nab-
rapamycin at days 3, 8, and 28. Figure 8B shows the endothelialization after periadventitial
delivery of Nab-rapamycin at days 3, 8, and 28.
Figure 9A shows adventitial leukocyte infiltration after periadventitial delivery of
Nab-rapamycin or a control at days 3, 8, and 28. Figure 9B shows mean number of adventitial
vessels after periadventitial delivery of Nab-rapamycin or a control at day 28.
Figure 10 shows re-endothelialization of target arteries after periadventitial
delivery of Nab-rapamycin or a control at days 3, 8, and 28.
DETAILED DESCRIPTION OF THE INVENTION
The present application describes methods of delivering a composition
comprising nanoparticles comprising a macrolide and an albumin (the “nanoparticle
composition”) to a blood vessel, wherein the method comprises injecting into the blood vessel
wall or tissue surrounding the blood vessel wall an effective amount of a composition
comprising nanoparticles comprising a macrolide and an albumin. Such method can be useful,
for example, for inhibiting negative remodeling in the blood vessel and/or inhibiting vascular
fibrosis in the blood vessel, and are thus useful for treating various diseases associated with
negative remodeling and/or vascular fibrosis.
Using a porcine femoral artery balloon injury model, it was shown that a
nanoparticle composition comprising a macrolide and an albumin, namely, Nanoparticle
Albumin-Bound (Nab) Rapamycin (Nab-Rapamycin), when injected into the periadventitial
tissue of a blood vessel, significantly decreased negative remodeling of the balloon-injured
blood vessel and medial fibrosis in the blood vessel. Within one hour after the injection, the
rapamycin level in the perivascular tissue was about 1500 times higher than that in the blood
within an hour, and rapamycin was retained in the perivascular tissue for at least 8 days.
Periadventitial injection of a nanoparticle composition therefore can be an effective method for
inhibiting negative remodeling, inhibiting vascular fibrosis, as well as for treating various
diseases associated with negative remodeling and/or vascular fibrosis.
The present application in one aspect provides a use of a composition comprising
nanoparticles comprising a macrolide and an albumin in the manufacture of a medicament for
treating a disease selected from the group consisting of angina, myocardial infarction, congestive
heart failure, cardiac arrhythmia, peripheral artery disease, claudication, and chronic limb
ischemia in an individual in need thereof, wherein the medicament is to be injected into a blood
vessel wall or tissue surrounding the blood vessel wall in the individual.
[0027a] In another aspect, the invention provides a use of a composition comprising
nanoparticles comprising a macrolide and an albumin in the manufacture of a medicament for
treating restenosis in a blood vessel in an individual in need thereof, wherein the medicament is
to be injected into the blood vessel wall or tissue surrounding the blood vessel wall.
[0027c] Also described is a method of inhibiting negative remodeling or vascular fibrosis
in the blood vessel of an individual in need thereof, comprising injecting into the blood vessel
wall or tissue surrounding the blood vessel wall an effective amount of a composition
comprising nanoparticles comprising a macrolide and an albumin.
Also described is a method of delivering a composition comprising nanoparticles
comprising a macrolide and an albumin to a blood vessel, wherein the method comprises
injecting into the blood vessel wall or tissue surrounding the blood vessel wall an effective
amount of a composition comprising nanoparticles comprising a macrolide and an albumin.
Further described are kits and devices (such as a catheter with a needle) that are
useful for the methods described herein.
Definitions
The term “individual” refers to a mammal and includes, but is not limited to,
human, bovine, horse, feline, canine, rodent, or primate.
It is understood that aspect and embodiments of the invention described herein
include “consisting” and/or “consisting essentially of” aspects and embodiments.
Reference to "about" a value or parameter herein includes (and describes)
variations that are directed to that value or parameter per se. For example, description referring
to "about X" includes description of "X".
As used herein and in the appended claims, the singular forms "a," "or," and "the"
include plural referents unless the context clearly dictates otherwise.
[0033a] The term “comprising” as used in this specification and claims means “consisting
at least in part of”. When interpreting statements in this specification, and claims which include
the term “comprising”, it is to be understood that other features that are additional to the features
prefaced by this term in each statement or claim may also be present. Related terms such as
“comprise” and “comprised” are to be interpreted in similar manner.
Methods of the present invention
The present application in some embodiments describes a method of delivering a
composition comprising nanoparticles comprising albumin and a macrolide (such as rapamycin
or a derivative thereof, for example rapamycin) to a blood vessel, wherein the method comprises
injecting into the blood vessel wall or tissue surrounding the blood vessel wall an effective
amount of a composition comprising nanoparticles comprising a macrolide and an albumin.
Also described is a method of delivering a composition comprising nanoparticles comprising
albumin and a macrolide (such as rapamycin) to a blood vessel, wherein the method comprises
injecting into the blood vessel wall or tissue surrounding the blood vessel wall an effective
amount of a composition comprising nanoparticles comprising a macrolide and an albumin (such
as human serum albumin), wherein the macrolide in the nanoparticles is coated with the
albumin. In some embodiments, there is described a method of delivering a composition
comprising nanoparticles comprising albumin and a macrolide (such as rapamycin) to a blood
vessel, wherein the method comprises injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of a composition comprising nanoparticles comprising
a macrolide and an albumin (such as human serum albumin), wherein the average particle size of
the nanoparticles in the composition is no greater than about 200 nm (such as less than about 200
nm, for example no greater than about 100 nm). In some embodiments, there is described a
method of delivering a composition comprising nanoparticles comprising albumin and a
macrolide (such as rapamycin) to a blood vessel, wherein the method comprises injecting into
the blood vessel wall or tissue surrounding the blood vessel wall an effective amount of a
composition comprising nanoparticles comprising rapamycin and an albumin (such as human
serum albumin), wherein the rapamycin in the nanoparticles is coated with the albumin, and
wherein the average particle size of the nanoparticles in the composition is no greater than about
200 nm (such as less than about 200 nm for example no greater than about 100 nm). In some
embodiments, there is described a method of delivering Nab-rapamycin to a blood vessel,
wherein the method comprises injecting into the blood vessel wall or tissue surrounding the
blood vessel wall an effective amount of Nab-rapamycin. In some embodiments, the
nanoparticle composition is injected at or adjacent to a disease site (or lesion site), such as no
more than about 2, 1, or 0.5 cm away from the disease site (or lesion site). In some
embodiments, the nanoparticle composition is injected remotely from a disease site (such
example at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away from the disease site).
A typical blood vessel wall has an endothelium which is the layer of the wall
which is exposed to the blood vessel lumen. Underlying the endothelium is the basement
membrane which in turn is surrounded by the intima. The intima, in turn, is surrounded by the
internal elastic lamina over which is located the media. In turn, the media is covered by the
external elastic lamina which acts as the outer barrier separating the blood vessel wall from the
adventitial tissue, which surrounds the blood vessel wall. The methods described herein include
injection of the nanoparticle composition into any one of these layers of the blood vessel wall.
In some embodiments, the nanoparticle composition is injected into the endothelium. In some
embodiments, the nanoparticle composition is injected into the basement membrane. In some
embodiments, the nanoparticle composition is injected into the intima. In some embodiments,
the nanoparticle composition is injected into the internal elastic lamina. In some embodiments,
the nanoparticle is injected into the media. In some embodiments, the nanoparticle is injected
into the external elastic lamina. In some embodiments, the nanoparticle composition is injected
into any one of the following regions of a blood vessel: tunica intima (contains endothelium,
basement membrane, internal elastic lamina), tunica media (contains smooth muscle cells), and
tunica adventitia (contains external elastic membrane, collagen fibres).
“Tissue surrounding the blood vessel wall,” used herein interchangeably with the
terms “perivascular” or “periadventitial,” refers to the region over the outer surface of the blood
vessel wall. This includes the adventitial tissue of the blood vessel, as well as regions beyond
the adventitial tissue. By controlling the site of the injection of the nanoparticle compositions,
the nanoparticle composition can be injected to the specific desired locations.
Methods and devices have been developed for the purpose of injecting
therapeutic agents into the blood vessel wall and tissues surrounding the blood vessel wall. For
example, catheters carrying needles capable of delivering therapeutic and other agents deep into
the adventitial layer surrounding blood vessel lumens have been described in U.S. Pat. No.
6,547,303, 6,860,867 and U.S. Patent Application Publication Nos. 2007/0106257,
2010/0305546, and 2009/0142306, the content of each of these are specifically incorporated
herein by reference in their entirety. The methods described herein in some embodiments use a
catheter having a needle for the injection of the nanoparticle composition. In some
embodiments, the needle is deployable. The catheter can be advanced intravascularly to a target
injection site (which may or may not be a disease region) in a blood vessel. The needle in the
catheter is advanced through the blood vessel wall so that an aperture on the needle is positioned
in the desired region (for example the perivascular region), and the nanoparticle compositions
can be injected through the aperture of the needled into the desired region.
For example, in some embodiments there is described a method of delivering a
composition comprising nanoparticles comprising albumin and a macrolide (such as rapamycin
or derivative thereof, for example rapamycin) to a blood vessel, wherein the method comprises
injecting (for example via a catheter with a needle) into the tissue surrounding the blood vessel
wall an effective amount of a composition comprising nanoparticles comprising a macrolide and
an albumin. In some embodiments, there is described a method of delivering a composition
comprising nanoparticles comprising albumin and a macrolide (such as rapamycin) to a blood
vessel, wherein the method comprises injecting (for example via a catheter with a needle) into
the tissue surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin (such as human serum albumin), wherein
the macrolide in the nanoparticles is coated with the albumin. In some embodiments, there is
described a method of delivering a composition comprising nanoparticles comprising albumin
and a macrolide (such as rapamycin) to a blood vessel, wherein the method comprises injecting
(for example via a catheter with a needle) into the tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising a macrolide and an
albumin (such as human serum albumin), wherein the average particle size of the nanoparticles
in the composition is no greater than about 200 nm (such as less than about 200 nm, for example
no greater than about 100 nm). In some embodiments, there is described a method of delivering
a composition comprising nanoparticles comprising albumin and a macrolide (such as
rapamycin) to a blood vessel, wherein the method comprises injecting (for example via a
catheter with a needle) into the tissue surrounding the blood vessel wall an effective amount of a
composition comprising nanoparticles comprising rapamycin and an albumin (such as human
serum albumin), wherein the rapamycin in the nanoparticles is coated with the albumin, and
wherein the average particle size of the nanoparticles in the composition is no greater than about
200 nm (such as less than about 200 nm for example no greater than about 100nm). In some
embodiments, there is described a method of delivering Nab-rapamycin to a blood vessel,
wherein the method comprises injecting (for example via a catheter with a needle) into the tissue
surrounding the blood vessel wall an effective amount of Nab-rapamycin. In some embodiments,
the nanoparticle composition is injected at a disease site. In some embodiments, the
nanoparticle composition is injected distal to a disease site (such example at least about any of 1,
2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away from the disease site).
In some embodiments, the nanoparticle composition is injected into the
adventitial tissue of the blood vessel. The adventitial tissue is the tissue surrounding the blood
vessel, for example the tissue beyond the external elastic lamina of an artery or beyond the
tunica media of a vein. The adventitia has a high concentration of lipid. In some embodiments,
the nanoparticle composition is injected into the vasa vasorum region of the adventitia. In some
embodiments, the nanoparticle composition, upon injection, can disperse through the adventitia
circumferentially, longitudinally, and/or transmurally from the injection site with respect to the
axis of the blood vessel from which the nanoparticle composition is being injected (herein after
referred to as “volumetric distribution”). In some embodiments, the drug (in an albumin-bound
form or in nanoparticle form) distributes over a distance of at least about 1 cm (for example at
least about any of 2 cm, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm, or more) longitudinally and/or at least 1
cm (for example at least about any of 2 cm, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm, or more) radially
from the site of injection over a time period no greater than 60 minutes. In some embodiments,
a concentration of a drug measured at all locations at least 2 cm from the delivery site is at least
% (such as at least about any of 20%, 30%, 40%, or 50%) of the concentration at the delivery
site, for example after a period of 60 minutes. In some embodiments, the drug (in an albumin-
bound form or in nanoparticle form) distributes transmurally throughout the endothelial and
intimal layers of the blood vessel, the media, and the muscular layer. While periadventitial
administration of pharmaceutical agents has previously been reported to allow volumetric
distribution of a pharmaceutical agent, it was believed larger substances are not efficiently
distributed because volumetric distribution was achieved by the lymphatic microcirculatory
system surrounding the blood vessel. The behavior of nanoparticle compositions in the
adventitial tissue was unknown. The present disclosure thus differs from methods previously
reported in these aspects.
Thus, in some embodiments, there is described a method of delivering a
composition comprising nanoparticles comprising albumin and a macrolide (such as rapamycin)
to a blood vessel, wherein the method comprises injecting (for example via a catheter with a
needle) into the adventitial tissue of the blood vessel wall an effective amount of a composition
comprising nanoparticles comprising a macrolide and an albumin. In some embodiments, there
is described a method of delivering a composition comprising nanoparticles comprising albumin
and a macrolide (such as rapamycin) to a blood vessel, wherein the method comprises injecting
(for example via a catheter with a needle) into the adventitial tissue of the blood vessel an
effective amount of a composition comprising nanoparticles comprising a macrolide and an
albumin (such as human serum albumin), wherein the macrolide in the nanoparticles is coated
with the albumin. In some embodiments, there is described a method of delivering a
composition comprising nanoparticles comprising albumin and a macrolide (such as rapamycin)
to a blood vessel, wherein the method comprises injecting (for example via a catheter with a
needle) into the adventitial tissue of the blood vessel an effective amount of a composition
comprising nanoparticles comprising a macrolide and an albumin (such as human serum
albumin), wherein the average particle size of the nanoparticles in the composition is no greater
than about 200 nm (such as less than about 200 nm, for example no greater than about 100 nm).
In some embodiments, there is described a method of delivering a composition comprising
nanoparticles comprising albumin and a macrolide (such as rapamycin) to a blood vessel,
wherein the method comprises injecting (for example via a catheter with a needle) into the
adventitial tissue of the blood vessel an effective amount of a composition comprising
nanoparticles comprising rapamycin and an albumin (such as human serum albumin), wherein
the rapamycin in the nanoparticles is coated with the albumin, and wherein the average particle
size of the nanoparticles in the composition is no greater than about 200 nm (such as less than
about 200 nm for example no greater than about 100 nm). In some embodiments, there is
described a method of delivering Nab-rapamycin to a blood vessel, wherein the method
comprises injecting (for example via a catheter with a needle) into the adventitial tissue of the
blood vessel wall an effective amount of Nab-rapamycin. In some embodiments, the
nanoparticle composition is injected at or adjacent to a disease site (such as no more than about
2, 1, or 0.5 cm away from the disease site). In some embodiments, the nanoparticle composition
is injected remotely from a disease site (such example at least about any of 1, 2, 3, 4, 5, 6, 7, 8,
9, or 10 cm away from the disease site). In some embodiments, the nanoparticle composition,
upon injection, achieves a volumetric distribution.
The blood vessel described in some embodiments is an artery, such as a coronary
artery or a peripheral artery. In some embodiments, the artery is selected from the group
consisting of renal artery, cerebral artery, pulmonary artery, and artery in the leg. In some
embodiments, the blood vessel is an artery or vein above the knee. In some embodiments, the
blood vessel is an artery or vein below the knee. In some embodiments, the blood vessel is a
femoral artery. In some embodiments, the blood vessel is a balloon injured artery.
In some embodiments, the blood vessel is an artery selected from any one of the
following: abdominal aorta, anterior tibial artery, arch of aorta, arcuate artery, axillary artery,
brachial artery, carotid artery, celiac artery, circumflex fibular artery, common hepatic artery,
common iliac artery, deep femoral artery, deep palmar arterial arch, dorsal digital artery, dorsal
metatarsal artery, external carotid artery, external iliac artery, facial artery, femoral artery,
inferior mesenteric artery, internal iliac artery, instestinal artery, lateral inferior genicular artery,
lateral superior genicular artery, palmar digital artery, peroneal artery, popliteal artery, posterior
tibial artery, profunda femoris artery, pulmonary artery, radial artery, renal artery, splenic artery,
subclavian artery, superficial palmar arterial arch, superior mesenteric artery, superior ulnar
collateral artery, and ulnar artery.
In some embodiments, the blood vessel is a vein. In some embodiments, the
blood vessel is a vein selected from any one of the following: accessory cephalic vein, axillary
vein, basilic vein, brachial vein, cephalic vein, common iliac vein, dorsal digital vein, dorsal
metatarsal vein, external iliac vein, facial vein, femoral vein, great saphenous vein, hepatic vein,
inferior mesenteric vein, inferior vena cava, intermediate antebrachial vein, internal iliac vein,
intestinal vein, jugular vein, lateral circumflex femoral vein, left inferior pulmonary vein, left
superior pulmonary vein, palmar digital vein, portal vein, posterior tibial vein, renal vein,
retromanibular vein, saphenous vein, small saphenous vein, splenic vein, subclavian vein,
superior mesenteric vein, and superior vena cava.
In some embodiments, the blood vessel is part of the coronary vasculature
(including the arterial and venous vasculature), the cerebral vasculature, the hepatic vasculature,
the peripheral vasculature, and the vasculature of other organs and tissue compartments.
In some embodiments, there is described a method of delivering a composition
comprising nanoparticles comprising albumin and a macrolide (such as a rapamycin or a
derivative thereof, for example rapamycin) to a blood vessel, wherein the method comprises
injecting (for example via a catheter with a needle) periadventitially (i.e., injecting into the
periadventitial tissue) to a femoral artery an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin. In some embodiments, there is described
a method of delivering a composition comprising nanoparticles comprising albumin and a
macrolide (such as a rapamycin or a derivative thereof, for example rapamycin) to a blood
vessel, wherein the method comprises injecting (for example via a catheter with a needle)
periadventitially to a femoral artery an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin (such as human serum albumin), wherein
the macrolide in the nanoparticles is coated with the albumin. In some embodiments, there is
described a method of delivering a composition comprising nanoparticles comprising albumin
and a macrolide (such as a rapamycin or a derivative thereof, for example rapamycin) to a blood
vessel, wherein the method comprises injecting (for example via a catheter with a needle)
periadventitially to a femoral artery an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin (such as human serum albumin), wherein
the average particle size of the nanoparticles in the composition is no greater than about 200 nm
(such as less than about 200 nm, for example no greater than about 100 nm). In some
embodiments, there is described a method of delivering a composition comprising nanoparticles
comprising albumin and a macrolide (such as a rapamycin or a derivative thereof, for example
rapamycin) to a blood vessel, wherein the method comprises injecting (for example via a
catheter with a needle) periadventitially to a femoral artery an effective amount of a composition
comprising nanoparticles comprising rapamycin and an albumin (such as human serum
albumin), wherein the rapamycin in the nanoparticles is coated with the albumin, and wherein
the average particle size of the nanoparticles in the composition is no greater than about 200 nm
(such as less than about 200 nm for example no greater than about 100 nm). In some
embodiments, there is described a method of delivering Nab-rapamycin to a blood vessel,
wherein the method comprises injecting (for example via a catheter with a needle)
periadventitially to a femoral artery an effective amount of Nab-rapamycin. In some
embodiments, the nanoparticle composition is injected at or adjacent to a disease site (such as no
more than about 2, 1, or 0.5 cm away from the disease site). In some embodiments, the
nanoparticle composition is injected remotely from a disease site (such example at least about
any of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away from the disease site).
The delivery methods described herein are effective in inhibiting one or more
aspects of blood vessel abnormalities, including for example, negative remodeling, vascular
fibrosis, restenosis, cell proliferation and migration of cells in the blood vessel, and wound
healing. In some embodiments, the method is effective in promoting positive remodeling of the
blood vessel.
The present application thus in some embodiments describes a method of
inhibiting negative remodeling in a blood vessel in an individual in need thereof, comprising
injecting into the blood vessel wall or tissue surrounding the blood vessel wall an effective
amount of a composition comprising nanoparticles comprising a macrolide (such as rapamycin)
and an albumin. In some embodiments, there is described a method of inhibiting negative
remodeling in a blood vessel in an individual in need thereof, comprising injecting into the blood
vessel wall or tissue surrounding the blood vessel wall an effective amount of a composition
comprising nanoparticles comprising a macrolide and an albumin (such as human serum
albumin), wherein the macrolide in the nanoparticles is coated with the albumin. In some
embodiments, there is described a method of inhibiting negative remodeling in a blood vessel in
an individual in need thereof, comprising injecting into the blood vessel wall or tissue
surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin (such as human serum albumin), wherein
the average particle size of the nanoparticles in the composition is no greater than about 200 nm
(such as less than about 200 nm, for example no greater than about 100 nm). In some
embodiments, there is described a method of inhibiting negative remodeling in a blood vessel in
an individual in need thereof, comprising injecting into the blood vessel wall or tissue
surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising rapamycin and an albumin (such as human serum albumin), wherein
the rapamycin in the nanoparticles is coated with the albumin, and wherein the average particle
size of the nanoparticles in the composition is no greater than about 200 nm (such as less than
about 200 nm for example no greater than about 100nm). In some embodiments, there is
described a method of inhibiting negative remodeling in a blood vessel in an individual in need
thereof, comprising injecting into the blood vessel wall or tissue surrounding the blood vessel
wall an effective amount of Nab-rapamycin. In some embodiments, the nanoparticle
composition is injected at or adjacent to a site of negative remodeling (such as no more than
about 2, 1, or 0.5 cm away from the site of negative remodeling). In some embodiments, the
nanoparticle composition is injected remotely from a site of negative remodeling (such example
at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away from the site of negative remodeling).
In some embodiments, the injection is via a catheter with a needle.
Negative remodeling includes the physiologic or pathologic response of a blood
vessel to a stimulus resulting in a reduction of vessel diameter and lumen diameter. Such a
stimulus could be provided by, for example, a change in blood flow or an angioplasty procedure.
In some embodiments, the injection of the nanoparticle composition leads to an increase of
vessel diameter by about any of 10%, 20%, 30%, 40%, 60%, 70%, 80%, 95%, or more,
compared to the diameter of a vessel of without the injection. Negative remodeling can be
quantified, for example, angiographically as the percent diameter stenosis at the lesion site (or
disease site). Another method of determining the degree of remodeling involves measuring in-
lesion external elastic lamina area using intravascular ultrasound (IVUS). IVUS is a technique
that can image the external elastic lamina as well as the vascular lumen. In some embodiments,
the negative remodeling is associated with a vascular interventional procedure, such as
angioplasty, stenting, or atherectomy. The nanoparticle composition can therefore be injected
during or after the vascular interventional procedure.
In some embodiments, there is described a method of promoting positive
remodeling in a blood vessel in an individual in need thereof, comprising injecting into the blood
vessel wall or tissue surrounding the blood vessel wall an effective amount of a composition
comprising nanoparticles comprising a macrolide (such as rapamycin) and an albumin. In some
embodiments, there is described a method of promoting positive remodeling in a blood vessel in
an individual in need thereof, comprising injecting into the blood vessel wall or tissue
surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin (such as human serum albumin), wherein
the macrolide in the nanoparticles is coated with the albumin. In some embodiments, there is
described a method of promoting positive remodeling in a blood vessel in an individual in need
thereof, comprising injecting into the blood vessel wall or tissue surrounding the blood vessel
wall an effective amount of a composition comprising nanoparticles comprising a macrolide and
an albumin (such as human serum albumin), wherein the average particle size of the
nanoparticles in the composition is no greater than about 200 nm (such as less than about 200
nm, for example no greater than about 100 nm). In some embodiments, there is described a
method of promoting positive remodeling in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising rapamycin and an
albumin (such as human serum albumin), wherein the rapamycin in the nanoparticles is coated
with the albumin, and wherein the average particle size of the nanoparticles in the composition is
no greater than about 200 nm (such as less than about 200 nm for example no greater than about
100nm). In some embodiments, there is described a method of promoting positive remodeling in
a blood vessel in an individual in need thereof, comprising injecting into the blood vessel wall or
tissue surrounding the blood vessel wall an effective amount of Nab-rapamycin. In some
embodiments, the nanoparticle composition is injected at or adjacent to a site of negative
remodeling (such as no more than about 2, 1, or 0.5 cm away from the site of negative
remodeling). In some embodiments, the nanoparticle composition is injected remotely from a
site of negative remodeling (such example at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm
away from the site of negative remodeling). In some embodiments, the injection is via a catheter
with a needle.
Positive remodeling used herein refers to an increase of vessel diameter as
compared to the diameter of a vessel without the injection. In some embodiments, the injection
of the nanoparticle composition leads to an increase of vessel diameter by about any of 10%,
%, 30%, 40%, 60%, 70%, 80%, 95%, or more, compared to the diameter of a vessel of
without the injection.
In some embodiments, there is described a method of inhibiting vascular fibrosis
(such as medial vascular fibrosis) in a blood vessel in an individual in need thereof, comprising
injecting into the blood vessel wall or tissue surrounding the blood vessel wall an effective
amount of a composition comprising nanoparticles comprising a macrolide (such as rapamycin)
and an albumin. In some embodiments, there is described a method of inhibiting vascular
fibrosis (such as medial vascular fibrosis) in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising a macrolide and an
albumin (such as human serum albumin), wherein the macrolide in the nanoparticles is coated
with the albumin. In some embodiments, there is described a method of inhibiting vascular
fibrosis (such as medial vascular fibrosis) in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising a macrolide and an
albumin (such as human serum albumin), wherein the average particle size of the nanoparticles
in the composition is no greater than about 200 nm (such as less than about 200 nm, for example
no greater than about 100 nm). In some embodiments, there is described a method of inhibiting
vascular fibrosis (such as medial vascular fibrosis) in a blood vessel in an individual in need
thereof, comprising injecting into the blood vessel wall or tissue surrounding the blood vessel
wall an effective amount of a composition comprising nanoparticles comprising rapamycin and
an albumin (such as human serum albumin), wherein the rapamycin in the nanoparticles is
coated with the albumin, and wherein the average particle size of the nanoparticles in the
composition is no greater than about 200 nm (such as less than about 200 nm for example no
greater than about 100nm). In some embodiments, there is described a method of inhibiting
vascular fibrosis (such as medial vascular fibrosis) in a blood vessel in an individual in need
thereof, comprising injecting into the blood vessel wall or tissue surrounding the blood vessel
wall an effective amount of Nab-rapamycin. In some embodiments, the nanoparticle
composition is injected at or adjacent to the site of vascular fibrosis (for example no greater than
about any of 2, 1, 0.5 cm away from the site of vascular fibrosis). In some embodiments, the
nanoparticle composition is injected remotely from a site of vascular fibrosis (such example at
least about any of 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away from the site of vascular fibrosis). In some
embodiments, the injection is via a catheter with a needle.
Vascular fibrosis as used herein refers to the extensive fibrous (connective) tissue
formation in the blood vessel, and includes, for example, medial fibrosis or adventitial fibrosis.
Vascular fibrosis is frequently associated with abundant deposition of extracellular matrix and
proliferation of myofibroblasts and fibroblasts. The method described herein therefore in some
embodiments inhibits fibrous tissue formation in the blood vessel, for example inhibits about
any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% fibrous tissue formation compared
to a vessel without the injection. In some embodiments, the method inhibits deposition of
extracellular matrix in the blood vessel, for example inhibits about any of 10%, 20%, 30%, 40%,
50%, 60%, 70%, 80%, or 90% deposition of extracellular matrix compared to a vessel without
the injection. In some embodiments, the method inhibits proliferation of myofibroblast in the
blood vessel, for example inhibits about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or
90% proliferation of myofibroblast compared to a vessel without the injection. In some
embodiments, the method inhibits proliferation of fibroblast in the blood vessel, for example
inhibits about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% proliferation of
fibroblast compared to a vessel without the injection. In some embodiments, the vascular
fibrosis is associated with a vascular interventional procedure, such as angioplasty, stenting, or
atherectomy. The nanoparticle composition can therefore be injected during or after the vascular
interventional procedure.
The method described herein therefore in some embodiments inhibits luminal
stenosis, for example inhibits about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%
luminal stenosis compared to a vessel without the injection. In some embodiments, the luminal
stenosis is associated with a vascular interventional procedure, such as angioplasty, stenting, or
atherectomy. The nanoparticle composition can therefore be injected during or after the vascular
interventional procedure.
In some embodiments, there is described a method of treating restenosis in a
blood vessel in an individual in need thereof, comprising injecting into the blood vessel wall or
tissue surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide (such as rapamycin) and an albumin. In some
embodiments, there is described a method of treating restenosis in a blood vessel in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of a composition comprising nanoparticles comprising
a macrolide and an albumin (such as human serum albumin), wherein the macrolide in the
nanoparticles is coated with the albumin. In some embodiments, there is described a method of
treating restenosis in a blood vessel in an individual in need thereof, comprising injecting into
the blood vessel wall or tissue surrounding the blood vessel wall an effective amount of a
composition comprising nanoparticles comprising a macrolide and an albumin (such as human
serum albumin), wherein the average particle size of the nanoparticles in the composition is no
greater than about 200 nm (such as less than about 200 nm, for example no greater than about
100 nm). In some embodiments, there is described a method of treating restenosis in a blood
vessel in an individual in need thereof, comprising injecting into the blood vessel wall or tissue
surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising rapamycin and an albumin (such as human serum albumin), wherein
the rapamycin in the nanoparticles is coated with the albumin, and wherein the average particle
size of the nanoparticles in the composition is no greater than about 200 nm (such as less than
about 200 nm for example no greater than about 100nm). In some embodiments, there is
described a method of treating restenosis in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of Nab-rapamycin. In some embodiments, the nanoparticle composition is
injected at or adjacent to a disease site (for example no more than about 2, 1, or 0.5 cm away
from the disease site). In some embodiments, the nanoparticle composition is injected remotely
from a disease site (such example at least about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away
from the disease site). In some embodiments, the injection is via a catheter with a needle.
In some embodiments, there is described a method of reducing adventitial
leukocytes in a blood vessel in an individual in need thereof, comprising injecting into the blood
vessel wall or tissue surrounding the blood vessel wall an effective amount of a composition
comprising nanoparticles comprising a macrolide (such as rapamycin) and an albumin. In some
embodiments, there is described a method of reducing adventitial leukocytes in a blood vessel in
an individual in need thereof, comprising injecting into the blood vessel wall or tissue
surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide and an albumin (such as human serum albumin), wherein
the macrolide in the nanoparticles is coated with the albumin. In some embodiments, there is
described a method of reducing adventitial leukocytes in a blood vessel in an individual in need
thereof, comprising injecting into the blood vessel wall or tissue surrounding the blood vessel
wall an effective amount of a composition comprising nanoparticles comprising a macrolide and
an albumin (such as human serum albumin), wherein the average particle size of the
nanoparticles in the composition is no greater than about 200 nm (such as less than about 200
nm, for example no greater than about 100 nm). In some embodiments, there is described a
method of reducing adventitial leukocytes in a blood vessel in an individual in need thereof,
comprising injecting into the blood vessel wall or tissue surrounding the blood vessel wall an
effective amount of a composition comprising nanoparticles comprising rapamycin and an
albumin (such as human serum albumin), wherein the rapamycin in the nanoparticles is coated
with the albumin, and wherein the average particle size of the nanoparticles in the composition is
no greater than about 200 nm (such as less than about 200 nm for example no greater than about
100 nm). In some embodiments, there is described a method of reducing adventitial leukocytes
in a blood vessel in an individual in need thereof, comprising injecting into the blood vessel wall
or tissue surrounding the blood vessel wall an effective amount of Nab-rapamycin. In some
embodiments, the nanoparticle composition is injected into the adventitial tissue.
In some embodiments, there is described a method of reducing adventitial vessels
in a blood vessel in an individual in need thereof, comprising injecting into the blood vessel wall
or tissue surrounding the blood vessel wall an effective amount of a composition comprising
nanoparticles comprising a macrolide (such as rapamycin) and an albumin. In some
embodiments, there is described a method of reducing adventitial vessels in a blood vessel in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of a composition comprising nanoparticles comprising
a macrolide and an albumin (such as human serum albumin), wherein the macrolide in the
nanoparticles is coated with the albumin. In some embodiments, there is described a method of
reducing adventitial vessels in a blood vessel in an individual in need thereof, comprising
injecting into the blood vessel wall or tissue surrounding the blood vessel wall an effective
amount of a composition comprising nanoparticles comprising a macrolide and an albumin (such
as human serum albumin), wherein the average particle size of the nanoparticles in the
composition is no greater than about 200 nm (such as less than about 200 nm, for example no
greater than about 100 nm). In some embodiments, there is described a method of reducing
adventitial vessels in a blood vessel in an individual in need thereof, comprising injecting into
the blood vessel wall or tissue surrounding the blood vessel wall an effective amount of a
composition comprising nanoparticles comprising rapamycin and an albumin (such as human
serum albumin), wherein the rapamycin in the nanoparticles is coated with the albumin, and
wherein the average particle size of the nanoparticles in the composition is no greater than about
200 nm (such as less than about 200 nm for example no greater than about 100nm). In some
embodiments, there is described a method of reducing adventitial vessels in a blood vessel in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of Nab-rapamycin. In some embodiments, the
nanoparticle composition is injected into the adventitial tissue.
In some embodiments, the individual is human. In some embodiments, the
individual is at least about any of 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 85 years old. In some
embodiments, the individual is of Asian ancestry. In some embodiments, the individual is a
male. In some embodiments, the individual is a female. In some embodiments, the individual
has a disease as discussed below.
The methods described herein are useful for treating a variety of diseases. These
include, for example, angina, aortic stenosis, arteriosclerosis obliterans, carotid artery stenosis,
cerebrovascular artery disease, cerebrovascular occlusive disease, coronary artery disease,
dilated cardiomyopathy, cardiomyopathy, ischemic cardiomyopathy, intermittent claudication,
peripheral artery stenosis, renal artery disease, restenosis, small vessel disease, stenosis, aortic
stenosis, Aortic valve stenosis, hyaline arteriolosclerosis, hyperplastic arteriosclerosis, mitrial
stenosis, pulmonary valve stenosis, tricuspid valve stenosis, deep vein thrombosis, peripheral
venous disease, and thrombophlebitis. The methods described herein may encompass the
treatment of any one or more of these diseases.
In some embodiments, the disease is selected from the group consisting of
angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, peripheral artery
disease, claudication, or chronic limb ischemia. Thus, for example, in some embodiments, there
is described a method of treating angina (or myocardial infarction, or congestive heart failure, or
cardiac arrhythmia, or peripheral artery disease, or claudication, or chronic limb ischemia) in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of a composition comprising nanoparticles comprising
a macrolide (such as rapamycin) and an albumin. In some embodiments, there is described a
method of treating angina (or myocardial infarction, or congestive heart failure, or cardiac
arrhythmia, or peripheral artery disease, or claudication, or chronic limb ischemia) in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of a composition comprising nanoparticles comprising
a macrolide and an albumin (such as human serum albumin), wherein the macrolide in the
nanoparticles is coated with the albumin. In some embodiments, there is described a method of
treating angina (or myocardial infarction, or congestive heart failure, or cardiac arrhythmia, or
peripheral artery disease, or claudication, or chronic limb ischemia) in an individual in need
thereof, comprising injecting into the blood vessel wall or tissue surrounding the blood vessel
wall an effective amount of a composition comprising nanoparticles comprising a macrolide and
an albumin (such as human serum albumin), wherein the average particle size of the
nanoparticles in the composition is no greater than about 200 nm (such as less than about 200
nm, for example no greater than about 100 nm). In some embodiments, there is described a
method of treating angina (or myocardial infarction, or congestive heart failure, or cardiac
arrhythmia, or peripheral artery disease, or claudication, or chronic limb ischemia) in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of a composition comprising nanoparticles comprising
rapamycin and an albumin (such as human serum albumin), wherein the rapamycin in the
nanoparticles is coated with the albumin, and wherein the average particle size of the
nanoparticles in the composition is no greater than about 200 nm (such as less than about 200
nm for example no greater than about 100nm). In some embodiments, there is described a
method of treating angina (or myocardial infarction, or congestive heart failure, or cardiac
arrhythmia, or peripheral artery disease, or claudication, or chronic limb ischemia) in an
individual in need thereof, comprising injecting into the blood vessel wall or tissue surrounding
the blood vessel wall an effective amount of Nab-rapamycin. In some embodiments, the
nanoparticle composition is injected at or adjacent to a disease site (for example no more than
about 2, 1, or 0.5 cm away from the disease site). In some embodiments, the nanoparticle
composition is injected remotely from a disease site (such example at least about any of 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10 cm away from the disease site). In some embodiments, the injection is via a
catheter with a needle. In some embodiments, the nanoparticle composition is injected during or
after the vascular interventional procedure, such as angioplasty, stenting, or atherectomy.
The methods described herein in some embodiments comprise injecting the
nanoparticle composition distal to the disease site. In some embodiments, the nanoparticle
composition is injected proximal to the disease site. The delivery site may be located within the
same blood vessel as the disease treatment region at a location which is longitudinally spaced-
apart from the region, or may be located in a different blood vessel. In some embodiments, the
nanoparticle composition is injected at or adjacent to the disease site (for example no more than
about any of 2, 1, or 0.5 cm away (for example longitudinally away) from the disease site). In
some embodiments, the nanoparticle composition is injected remotely from the disease site (for
example about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm away (for example longitudinally away)
from the disease site). In some embodiments, the disease treatment region may have been
previously stented where the delivery site is spaced away from the stent, either longitudinally
away from the stent in the same coronary artery or remote from the stent in another coronary
artery or vein.
The methods described herein in some embodiments comprise injecting the
nanoparticle composition with a needle (such as a deployable needle). The needle can be
positioned such that the nanoparticle composition is delivered to a desired site. The methods in
some embodiments thus comprise positioning a needle through the wall of a blood vessel and
delivering an effective amount of the nanoparticle composition into the wall of the blood vessel
or the tissue surrounding the blood vessel wall. For example, in some embodiments, the
aperture of the needle lies beyond the external elastic lamina of the blood vessel so that the
nanoparticle composition is delivered to the adventitial tissue surrounding the blood vessel. In
some embodiments, the aperture of the needle is positioned at a distance that is no more than
about 0.1 mm, about 0.2 mm, 0.5 mm, 0.8 mm, 1 cm, 2 cm, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm, or 8
cm beyond the external elastic lamina of the blood vessel.
In some embodiments, the aperture is positioned at a distance from the inner wall
of the blood vessel that is at least about 10% (including for example at least about 20%, 30%,
40%, 60%, 70%, 80%, 90%) of the mean luminal diameter of the blood vessel at the injection
site. In some embodiments, the aperture is positioned at a distance from the inner wall of the
blood vessel that is about 10% to about 75% (including for example about 20% to about 60%,
about 30% to about 50%) of the mean luminal diameter of the blood vessel at the injection site.
Confirmation of the position of the needle aperture can be achieved in a variety of
ways. For example, a bolus of contrast agent or other visible media can be injected through the
needle after initial positioning of the needle is achieved. By observing the distribution of the
media, for example fluroscopically, the position of the aperture can be assessed. In some
embodiments, various sensors can be attached or otherwise coupled to the needle, usually near
the delivery aperture, in order to detect the position of the needle. Exemplary sensors include
temperature sensors, pH sensors, electrical impedance sensors, and the like. It is also possible to
measure the back pressure on an injected suspension in order to determine the needle position.
Injection into the blood vessel wall will typically result in a greater back pressure than injection
into the adventitial space. It is also possible to monitor the insertion force of the needle, e.g., by
providing a deflection gauge on a portion of the needle.
Dosing and Method of Administering the Nanoparticle Compositions
The dose of the macrolide nanoparticle compositions injected to an individual
(such as a human) may vary with the type of blood vessel for the injection, the purpose of the
method, and the type of disease being treated. In some embodiments, the amount of the
macrolide nanoparticle composition injected is sufficient to inhibit negative remodeling by more
than about any of 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 64%,
65%, 70%, 75%, 80%, 85%, or 90%. Inhibition of negative remodeling can be assessed, for
example, by measuring the vessel or luminal diameter of the blood vessel. In some
embodiments, the amount of the macrolide nanoparticle composition injected is sufficient to
promote positive remodeling by more than about any of 5%, 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90%.
In some embodiments, the amount of the macrolide nanoparticle composition
injected is sufficient to inhibit vascular fibrosis by more than about any of 5%, 10%, 15%, 20%,
%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90%. In
some embodiments, the vascular fibrosis is medial fibrosis. In some embodiments, the vascular
fibrosis is adventitial fibrosis. Inhibition of vascular fibrosis can be assessed, for example, by
evaluating the amount of extracellular matrix deposition and/or proliferation of myofibroblasts
and fibroblasts. In some embodiments, the vascular fibrosis is evaluated by histopathology
analysis, for example by staining with H&E or trichrome.
In some embodiments, the amount of the macrolide nanoparticle composition
injected is sufficient to reduce proliferation index by more than about any of 5%, 10%, 15%,
%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90%.
In some embodiments, the amount of the macrolide nanoparticle composition injected is
sufficient to reduce luminal stenosis by more than about any of 5%, 10%, 15%, 20%, 25%, 30%,
%, 40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90%. In some
embodiments, the amount of the macrolide nanoparticle composition injected is sufficient to
reduce adventitial leukocytes by more than about any of 5%, 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 55%, 60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90%. In some embodiments,
the amount of the macrolide nanoparticle composition injected is sufficient to reduce adventitial
vessels by more than about any of 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 64%, 65%, 70%, 75%, 80%, 85%, or 90%.
In some embodiments, the amount of the macrolide (e.g., rapamycin) in the
composition is below the level that induces a toxicological effect (i.e., an effect above a
clinically acceptable level of toxicity) or is at a level where a potential side effect can be
controlled or tolerated when the composition is injected to the individual.
In some embodiments, the amount of a macrolide (e.g., rapamycin or derivative
thereof, for example rapamycin) per injection is within any one of the following ranges: about
0.001 to about 100 mg, including for example about 0.001 to about 0.005 mg, about 0.005 to
about 0.025 mg, about 0.025 to about 0.1 mg, about 0.1 to about 0.5 mg, about 0.5 to about 1mg,
about 1 to about 2 mg, about 2 to about 3 mg, about 3 to about 4 mg, about 4 to about 5 mg,
about 5 to about 6 mg, about 6 to about 7 mg, about 7 to about 8 mg, about 8 to about 9 mg,
about 9 to about 10 mg, about 10 to about 15 mg, about 15 to about 20 mg, about 20 to about 25
mg, about 20 to about 50 mg, about 25 to about 50 mg, about 50 to about 75 mg, or about 50 to
about 100 mg. In some embodiments, the amount of a macrolide (e.g., rapamycin) per injection
is in the range of about 0.001 to about 100 mg, such as about 0.005 to about 80 mg, about 0.05
to about 50 mg, about 0.1 to about 10 mg, about 0.1 to about 5 mg, about 0.5 to about 5 mg,
about 0.05 to about 5 mg, or about 0.5 to about 2 mg.
In some embodiments, the concentration of the macrolide (e.g., rapamycin) in the
nanoparticle composition is dilute (about 0.1 mg/ml) or concentrated (about 100 mg/ml),
including for example any of about 0.1 to about 50 mg/ml, about 0.1 to about 20 mg/ml, about 1
to about 10 mg/ml, about 2 mg/ml to about 8 mg/ml, about 4 to about 6 mg/ml, or about 5
mg/ml. In some embodiments, the concentration of the macrolide (e.g., rapamycin) is at least
about any of 0.5 mg/ml, 1.3 mg/ml, 1.5 mg/ml, 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml,
7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, or
50 mg/ml. In some embodiments, the concentration of the macrolide (e.g., rapamycin) is no
more than about any of 100 mg/ml, 90 mg/ml, 80 mg/ml, 70 mg/ml, 60 mg/ml, 50 mg/ml, 40
mg/ml, 30 mg/ml, 20 mg/ml, 10 mg/ml, or 5 mg/ml.
The volume of the nanoparticle composition per injection may vary with the type
of blood vessel for the injection, the purpose of the method, and the type of disease being
treated. In some embodiments, the volume per injection is about 0.01 to about 50 ml, including
for example about 0.01 to about 0.05 ml, about 0.05 to about 0.1 ml, about 0.1 to about 0.5 ml,
about 0.5 to about 1ml, about 1 to about 2 ml, about 2 to about 3 ml, about 3 to about 5 ml, about
to about 10 ml, about 10 to about 20 ml, about 20 to about 30 ml, about 30 to about 40 ml,
about 40 to about 50 ml. In some embodiments, the volume per injection is about 0.05 to about
2 ml, about 0.1 to 1 ml, about 0.25 to about 0.5 ml, or about 0.5 to about 1ml, or about 1 to about
ml.
Exemplary dosing frequencies for the administration of the nanoparticle
compositions include, but are not limited to, about once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or
12 months. In some embodiments, the intervals between each administration are more than
about any of 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, or 12
months. In some embodiments, the administration is administered every 3, 6, 9, 12, 15, 18, 21,
or 24 months. In some embodiments, the administration is administered at most every 3, 6, 9,
12, 15, 18, 21, or 24 months. In some embodiments, the administration is administered at least
every 3, 6, 9, 12, 15, 18, 21, or 24 months. In some embodiments, the nanoparticle composition
is injected only once.
The nanoparticle composition can be injected during a vascular interventional
procedure. In some embodiments, the nanoparticle composition is injected once during the
vascular interventional procedure. In some embodiments, the nanoparticle composition is
injected after a vascular interventional procedure. Exemplary vascular interventional procedures
include, but are not limited to, angioplasty, stenting, and atherectomy.
Nanoparticle Compositions
The nanoparticle compositions described herein comprise nanoparticles
comprising (in various embodiments consisting essentially of or consisting of) a macrolide (such
as rapamycin) and an albumin (such as human serum albumin). Nanoparticles of poorly water
soluble drugs (such as macrolide) have been disclosed in, for example, U.S. Pat. Nos. 5,916,596;
6,506,405; 6,749,868, 6,537,579, 7,820,788, and also in U.S. Pat. Pub. Nos. 2006/0263434, and
2007/0082838; PCT Patent Application WO08/137148, each of which is incorporated by
reference in their entirety.
In some embodiments, the composition comprises nanoparticles with an average
or mean diameter of no greater than about 1000 nanometers (nm), such as no greater than about
any of 900, 800, 700, 600, 500, 400, 300, 200, and 100 nm. In some embodiments, the average
or mean diameters of the nanoparticles is no greater than about 200 nm. In some embodiments,
the average or mean diameters of the nanoparticles is no greater than about 150 nm. In some
embodiments, the average or mean diameters of the nanoparticles is no greater than about 100
nm. In some embodiments, the average or mean diameter of the nanoparticles is about 20 to
about 400 nm. In some embodiments, the average or mean diameter of the nanoparticles is
about 40 to about 200 nm. In some embodiments, the average or mean diameter of the
nanoparticles is about 50 to about 100 nm. In some embodiments, the nanoparticles are no less
than about 50 nm. In some embodiments, the nanoparticles are sterile-filterable.
In some embodiments, the nanoparticles in the composition described herein have
an average diameter of no greater than about 200 nm, including for example no greater than
about any one of 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, or 60 nm. In
some embodiments, at least about 50% (for example at least about any one of 60%, 70%, 80%,
90%, 95%, or 99%) of the nanoparticles in the composition have a diameter of no greater than
about 200 nm, including for example no greater than about any one of 190, 180, 170, 160, 150,
140, 130, 120, 110, 100, 90, 80, 70, or 60 nm.
In some embodiments, the nanoparticles in the composition described herein have
an average diameter of no less than about 50 nm, including for example no less than about any
one of 50, 60, 70, 80, 90, or 100 nm. In some embodiments, at least about 50% (for example at
least about any one of 60%, 70%, 80%, 90%, 95%, or 99%) of the nanoparticles in the
composition have a diameter of no less than about 50 nm, including for example no less than
about any one of 50, 60, 70, 80, 90, or 100 nm.
In some embodiments, at least about 50% (for example at least any one of 60%,
70%, 80%, 90%, 95%, or 99%) of the nanoparticles in the composition fall within the range of
about 20 to about 400 nm, including for example about 20 to about 200 nm, about 40 to about
200 nm, about 30 to about 180 nm, and any one of about 40 to about 150, about 50 to about 120,
and about 60 to about 100 nm.
In some embodiments, the albumin has sulfhydral groups that can form disulfide
bonds. In some embodiments, at least about 5% (including for example at least about any one of
%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) of the albumin in the
nanoparticle portion of the composition are crosslinked (for example crosslinked through one or
more disulfide bonds).
In some embodiments, the nanoparticles comprise the macrolide (such as
rapamycin) coated with an albumin (e.g., human serum albumin). In some embodiments, the
composition comprises a macrolide in both nanoparticle and non-nanoparticle forms (e.g., in the
form of rapamycin solutions or in the form of soluble albumin/nanoparticle complexes), wherein
at least about any one of 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the macrolide in the
composition are in nanoparticle form. In some embodiments, the macrolide in the nanoparticles
constitutes more than about any one of 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the
nanoparticles by weight. In some embodiments, the nanoparticles have a non-polymeric matrix.
In some embodiments, the nanoparticles comprise a core of a macrolide that is substantially free
of polymeric materials (such as polymeric matrix).
In some embodiments, the composition comprises albumin in both nanoparticle
and non-nanoparticle portions of the composition, wherein at least about any one of 50%, 60%,
70%, 80%, 90%, 95%, or 99% of the albumin in the composition are in non-nanoparticle portion
of the composition.
In some embodiments, the weight ratio of albumin ( such as human serum
albumin) and a macrolide in the nanoparticle composition is about 18:1 or less, such as about
:1 or less, for example about 10:1 or less. In some embodiments, the weight ratio of albumin (
such as human serum albumin) and macrolide in the composition falls within the range of any
one of about 1:1 to about 18:1, about 2:1 to about 15:1, about 3:1 to about 13:1, about 4:1 to
about 12:1, about 5:1 to about 10:1. In some embodiments, the weight ratio of albumin and
macrolide in the nanoparticle portion of the composition is about any one of 1:2, 1:3, 1:4, 1:5,
1:10, 1:15, or less. In some embodiments, the weight ratio of the albumin ( such as human
serum albumin) and the macrolide in the composition is any one of the following: about 1:1 to
about 18:1, about 1:1 to about 15:1, about 1:1 to about 12:1, about 1:1 to about 10:1, about 1:1 to
about 9:1, about 1:1 to about 8:1, about 1:1 to about 7:1, about 1:1 to about 6:1, about 1:1 to
about 5:1, about 1:1 to about 4:1, about 1:1 to about 3:1, about 1:1 to about 2:1, or about 1:1.
In some embodiments, the nanoparticle composition comprises one or more of
the above characteristics.
The nanoparticles described herein may be present in a dry formulation (such as
lyophilized composition) or suspended in a biocompatible medium. Suitable biocompatible
media include, but are not limited to, water, buffered aqueous media, saline, buffered saline,
optionally buffered solutions of amino acids, optionally buffered solutions of proteins, optionally
buffered solutions of sugars, optionally buffered solutions of vitamins, optionally buffered
solutions of synthetic polymers, lipid-containing emulsions, and the like.
In some embodiments, the pharmaceutically acceptable carrier comprises human
serum albumin. Human serum albumin (HSA) is a highly soluble globular protein of M 65K
and consists of 585 amino acids. HSA is the most abundant protein in the plasma and accounts
for 70-80 % of the colloid osmotic pressure of human plasma. The amino acid sequence of HSA
contains a total of 17 disulphide bridges, one free thiol (Cys 34), and a single tryptophan (Trp
214). Intravenous use of HSA solution has been indicated for the prevention and treatment of
hypovolumic shock (see, e.g., Tullis, JAMA, 237, 355-360, 460-463, (1977)) and Houser et al.,
Surgery, Gynecology and Obstetrics, 150, 811-816 (1980)) and in conjunction with exchange
transfusion in the treatment of neonatal hyperbilirubinemia (see, e.g., Finlayson, Seminars in
Thrombosis and Hemostasis, 6, 85-120, (1980)). Other albumins are contemplated, such as
bovine serum albumin. Use of such non-human albumins could be appropriate, for example, in
the context of use of these compositions in non-human mammals, such as the veterinary
(including domestic pets and agricultural context).
Human serum albumin (HSA) has multiple hydrophobic binding sites (a total of
eight for fatty acids, an endogenous ligand of HSA) and binds a diverse set of macrolides,
especially neutral and negatively charged hydrophobic compounds (Goodman et al., The
Pharmacological Basis of Therapeutics, 9 ed, McGraw-Hill New York (1996)). Two high
affinity binding sites have been proposed in subdomains IIA and IIIA of HSA, which are highly
elongated hydrophobic pockets with charged lysine and arginine residues near the surface which
function as attachment points for polar ligand features (see, e.g., Fehske et al., Biochem.
Pharmcol., 30, 687-92 (198a), Vorum, Dan. Med. Bull., 46, 379-99 (1999), Kragh-Hansen,
Dan. Med. Bull., 1441, 131-40 (1990), Curry et al., Nat. Struct. Biol., 5, 827-35 (1998), Sugio et
al., Protein. Eng., 12, 439-46 (1999), He et al., Nature, 358, 209-15 (199b), and Carter et al.,
Adv. Protein. Chem., 45, 153-203 (1994)). Rapamycin and propofol have been shown to bind
HSA (see, e.g., Paal et al., Eur. J. Biochem., 268(7), 2187-91 (200a), Purcell et al., Biochim.
Biophys. Acta, 1478(a), 61-8 (2000), Altmayer et al., Arzneimittelforschung, 45, 1053-6 (1995),
and Garrido et al., Rev. Esp. Anestestiol. Reanim., 41, 308-12 (1994)). In addition, docetaxel has
been shown to bind to human plasma proteins (see, e.g., Urien et al., Invest. New Drugs, 14(b),
147-51 (1996)).
The albumin ( such as human serum albumin) in the composition generally serves
as a carrier for the macrolide, i.e., the albumin in the composition makes the macrolide more
readily suspendable in an aqueous medium or helps maintain the suspension as compared to
compositions not comprising an albumin. This can avoid the use of toxic solvents (or
surfactants) for solubilizing the macrolide, and thereby can reduce one or more side effects of
administration of the macrolide into an individual (such as a human). Thus, in some
embodiments, the composition described herein is substantially free (such as free) of surfactants,
such as Cremophor (including Cremophor EL (BASF)). In some embodiments, the
nanoparticle composition is substantially free (such as free) of surfactants. A composition is
“substantially free of Cremophor” or “substantially free of surfactant” if the amount of
Cremophor or surfactant in the composition is not sufficient to cause one or more side effect(s)
in an individual when the nanoparticle composition is injected to the individual. In some
embodiments, the nanoparticle composition contains less than about any one of 20%, 15%, 10%,
7.5%, 5%, 2.5%, or 1% organic solvent or surfactant.
The amount of albumin in the composition described herein will vary depending
on other components in the composition. In some embodiments, the composition comprises an
albumin in an amount that is sufficient to stabilize the macrolide in an aqueous suspension, for
example, in the form of a stable colloidal suspension (such as a stable suspension of
nanoparticles). In some embodiments, the albumin is in an amount that reduces the
sedimentation rate of the macrolide in an aqueous medium. For particle-containing
compositions, the amount of the albumin also depends on the size and density of nanoparticles
of the macrolide.
A macrolide is “stabilized” in an aqueous suspension if it remains suspended in
an aqueous medium (such as without visible precipitation or sedimentation) for an extended
period of time, such as for at least about any of 0.1, 0.2, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 24, 36, 48, 60, or 72 hours. The suspension is generally, but not necessarily, suitable for
administration to an individual (such as human). Stability of the suspension is generally (but not
necessarily) evaluated at a storage temperature (such as room temperature (such as 20-25 ºC) or
refrigerated conditions (such as 4 ºC)). For example, a suspension is stable at a storage
temperature if it exhibits no flocculation or particle agglomeration visible to the naked eye or
when viewed under the optical microscope at 1000 times, at about fifteen minutes after
preparation of the suspension. Stability can also be evaluated under accelerated testing
conditions, such as at a temperature that is higher than about 40 ºC.
In some embodiments, the albumin is present in an amount that is sufficient to
stabilize the macrolide in an aqueous suspension at a certain concentration. For example, the
concentration of the macrolide in the composition is about 0.1 to about 100 mg/ml, including for
example any of about 0.1 to about 50 mg/ml, about 0.1 to about 20 mg/ml, about 1 to about 10
mg/ml, about 2 mg/ml to about 8 mg/ml, about 4 to about 6 mg/ml, about 5 mg /ml. In some
embodiments, the concentration of the macrolide is at least about any of 1.3 mg/ml, 1.5 mg/ml, 2
mg/ml, 3 mg/ml, 4 mg/ml, 5 mg/ml, 6 mg/ml, 7 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml, 15 mg/ml,
mg/ml, 25 mg/ml, 30 mg/ml, 40 mg/ml, and 50 mg/ml. In some embodiments, the albumin is
present in an amount that avoids use of surfactants (such as Cremophor), so that the composition
is free or substantially free of surfactant (such as Cremophor).
In some embodiments, the composition, in liquid form, comprises from about
0.1% to about 50% (w/v) (e.g. about 0.5% (w/v), about 5% (w/v), about 10% (w/v), about 15%
(w/v), about 20% (w/v), about 30% (w/v), about 40% (w/v), or about 50% (w/v)) of albumin. In
some embodiments, the composition, in liquid form, comprises about 0.5% to about 5% (w/v) of
albumin.
In some embodiments, the weight ratio of albumin, e.g., albumin, to the
macrolide in the nanoparticle composition is such that a sufficient amount of macrolide binds to,
or is transported by, the cell. While the weight ratio of albumin to macrolide will have to be
optimized for different albumin and macrolide combinations, generally the weight ratio of
albumin, e.g., albumin, to macrolide (w/w) is about 0.01:1 to about 100:1, about 0.02:1 to about
50:1, about 0.05:1 to about 20:1, about 0.1:1 to about 20:1, about 1:1 to about 18:1, about 2:1 to
about 15:1, about 3:1 to about 12:1, about 4:1 to about 10:1, about 5:1 to about 9:1, or about 9:1.
In some embodiments, the albumin to macrolide weight ratio is about any of 18:1 or less, 15:1 or
less, 14:1 or less, 13:1 or less, 12:1 or less, 11:1 or less, 10:1 or less, 9:1 or less, 8:1 or less, 7:1
or less, 6:1 or less, 5:1 or less, 4:1 or less, and 3:1 or less. In some embodiments, the weight
ratio of the albumin ( such as human serum albumin) to the macrolide in the composition is any
one of the following: about 1:1 to about 18:1, about 1:1 to about 15:1, about 1:1 to about 12:1,
about 1:1 to about 10:1, about 1:1 to about 9:1, about 1:1 to about 8:1, about 1:1 to about 7:1,
about 1:1 to about 6:1, about 1:1 to about 5:1, about 1:1 to about 4:1, about 1:1 to about 3:1,
about 1:1 to about 2:1, or about 1:1.
In some embodiments, the albumin allows the composition to be injected to an
individual (such as human) without significant side effects. In some embodiments, the albumin (
such as human serum albumin) is in an amount that is effective to reduce one or more side
effects of administration of the macrolide to a human. The term “reducing one or more side
effects of administration of the macrolide” refers to reduction, alleviation, elimination, or
avoidance of one or more undesirable effects caused by the macrolide, as well as side effects
caused by delivery vehicles (such as solvents that render the macrolides suitable for injection)
used to deliver the macrolide. Such side effects include, for example, myelosuppression,
neurotoxicity, hypersensitivity, inflammation, venous irritation, phlebitis, pain, skin irritation,
peripheral neuropathy, neutropenic fever, anaphylactic reaction, venous thrombosis,
extravasation, and combinations thereof. These side effects, however, are merely exemplary and
other side effects, or combination of side effects, associated with macrolides can be reduced.
In some embodiments, the nanoparticle composition comprises Nab-rapamycin
(Celgene Corp.). In some embodiments, the nanoparticle composition is Nab-rapamycin. Nab-
rapamycin is a formulation of rapamycin stabilized by human albumin USP, which can be
dispersed in directly injectable physiological solution. When dispersed in a suitable aqueous
medium such as 0.9% sodium chloride injection or 5% dextrose injection, Nab-rapamycin forms
a stable colloidal suspension of rapamycin. The mean particle size of the nanoparticles in the
colloidal suspension is about 90 nanometers. Since HSA is freely soluble in water, Nab-
rapamycin can be reconstituted in a wide range of concentrations ranging from dilute (0.1 mg/ml
rapamycin) to concentrated (20 mg/ml rapamycin), including for example about 2 mg/ml to
about 8 mg/ml, or about 5 mg/ml.
Methods of making nanoparticle compositions are known in the art. For
example, nanoparticles containing macrolides (such as rapamycin) and albumin ( such as human
serum albumin) can be prepared under conditions of high shear forces (e.g., sonication, high
pressure homogenization, or the like). These methods are disclosed in, for example, U.S. Pat.
Nos. 5,916,596; 6,506,405; 6,749,868, 6,537,579 and 7,820,788 and also in U.S. Pat. Pub. Nos.
2007/0082838, 2006/0263434 and PCT Application WO08/137148.
Briefly, the macrolide (such as rapamycin) is dissolved in an organic solvent, and
the solution can be added to an albumin solution. The mixture is subjected to high pressure
homogenization. The organic solvent can then be removed by evaporation. The dispersion
obtained can be further lyophilized. Suitable organic solvent include, for example, ketones,
esters, ethers, chlorinated solvents, and other solvents known in the art. For example, the
organic solvent can be methylene chloride or chloroform/ethanol (for example with a ratio of
1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, or 9:1).
Other Components in the Nanoparticle Compositions
The nanoparticles described herein can be present in a composition that include
other agents, excipients, or stabilizers. For example, to increase stability by increasing the
negative zeta potential of nanoparticles, one or more of negatively charged components may be
added. Such negatively charged components include, but are not limited to bile salts of bile
acids consisting of glycocholic acid, cholic acid, chenodeoxycholic acid, taurocholic acid,
glycochenodeoxycholic acid, taurochenodeoxycholic acid, litocholic acid, ursodeoxycholic acid,
dehydrocholic acid and others; phospholipids including lecithin (egg yolk) based phospholipids
which include the following phosphatidylcholines: palmitoyloleoylphosphatidylcholine,
palmitoyllinoleoylphosphatidylcholine , stearoyllinoleoylphosphatidylcholine
stearoyloleoylphosphatidylcholine, stearoylarachidoylphosphatidylcholine, and
dipalmitoylphosphatidylcholine. Other phospholipids including L-α-
dimyristoylphosphatidylcholine (DMPC), dioleoylphosphatidylcholine (DOPC),
distearyolphosphatidylcholine (DSPC), hydrogenated soy phosphatidylcholine (HSPC), and
other related compounds. Negatively charged surfactants or emulsifiers are also suitable as
additives, e.g., sodium cholesteryl sulfate and the like.
In some embodiments, the composition is suitable for administration to a human.
In some embodiments, the composition is suitable for administration to a mammal such as, in the
veterinary context, domestic pets and agricultural animals. There are a wide variety of suitable
formulations of the nanoparticle composition (see, e.g., U.S. Pat. Nos. 5,916,596, 6,096,331, and
7,820,788). The following formulations and methods are merely exemplary and are in no way
limiting. Formulations suitable for oral administration can consist of (a) liquid solutions, such as
an effective amount of the compound dissolved in diluents, such as water, saline, or orange
juice, (b) capsules, sachets or tablets, each containing a predetermined amount of the active
ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable
emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch,
microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc,
magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents,
moistening agents, preservatives, flavoring agents, and pharmacologically compatible
excipients. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and
acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as
gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition
to the active ingredient, such excipients as are known in the art.
Examples of suitable carriers, excipients, and diluents include, but are not limited
to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate,
alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, water, saline solution, syrup, methylcellulose, methyl- and propylhydroxybenzoates,
talc, magnesium stearate, and mineral oil. The formulations can additionally include lubricating
agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents
or flavoring agents.
Formulations suitable for parenteral administration such as injection include
aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants,
buffers, bacteriostats, and solutes that render the formulation compatible with the blood of the
intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending
agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be
presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be
stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid
excipient, for example, water, for injections, immediately prior to use. Extemporaneous
injection solutions and suspensions can be prepared from sterile powders, granules, and tablets
of the kind previously described. Injectable formulations are preferred.
In some embodiments, the composition is formulated to have a pH range of about
4.5 to about 9.0, including for example pH ranges of any of about 5.0 to about 8.0, about 6.5 to
about 7.5, and about 6.5 to about 7.0. In some embodiments, the pH of the composition is
formulated to no less than about 6, including for example no less than about any of 6.5, 7, or 8
(such as about 8). The composition can also be made to be isotonic with blood by the addition
of a suitable tonicity modifier, such as glycerol.
Kits and Devices
Also described are kits and devices for use in any of the methods described
herein.
For example, in some embodiments, there is described a catheter with a needle
(such as a deployable needle), wherein the needle contains a composition comprising
nanoparticle comprising a macrolide (such as rapamycin) and an albumin. In some
embodiments, there is described a catheter with a needle (such as a deployable needle), wherein
the needle contains a composition comprising nanoparticle comprising a macrolide (such as
rapamycin) coated with an albumin. In some embodiments, there is described a catheter with a
needle (such as a deployable needle), wherein the needle contains a composition comprising
nanoparticle comprising a macrolide (such as rapamycin) and an albumin, wherein the average
particle size of the nanoparticles in the composition is no greater than about 200 nm (such as less
than about 200 nm, for example no greater than about 100 nm). In some embodiments, there is
described a catheter with a needle (such as a deployable needle), wherein the needle contains a
composition comprising nanoparticle comprising a macrolide (such as rapamycin) coated with
an albumin, wherein the average particle size of the nanoparticles in the composition is no
greater than about 200 nm (such as less than about 200 nm, for example no greater than about
100 nm). In some embodiments, there is described a catheter with a needle (such as a
deployable needle), wherein the needle contains Nab-rapamycin. In some embodiments, the
needle is sheathed in a balloon. In some embodiments the diameter of the needle is about 0.1 to
about 3 mm, including for example about 0.2 to about 2 mm, about 0.5 to about 1 mm, about 0.6
to about 0.9 mm, or about 0.9 mm. The length of the needle is typically between about 20 and
3000 microns, including for example between about 20-50, about 50-100, about 100-200, about
200-300, about 300-400, about 400-500, about 500-600, about 600-700, about 700-800, about
800-900, about 1-2, and about 2-3 microns. In some embodiments, the catheter contains more
than 1 (such as 2, 3, 4, 5, 6, 7, or more) needles.
Also described are kits comprising one or more containers comprising macrolide-
containing nanoparticle compositions (or unit dosage forms and/or articles of manufacture) and
in some embodiments, further comprise instructions for use in accordance with any of the
methods described herein. In some embodiments, the kit comprises a catheter having a needle
which can be advanced from a blood vessel lumen through a wall of the blood vessel (for
example to position an aperture of the needle beyond an external elastic lamina of the wall), and
a nanoparticle composition comprising a macrolide and albumin, wherein the nanoparticle
composition is injectable through the needle. In some embodiments, the kit further comprises a
syringe. In some embodiments, the syringe is filled up with an effective amount of the
nanoparticle composition.
The kit may further comprise a description of selection of individual suitable for
treatment. Instructions supplied in the kits described herein are typically written instructions on
a label or package insert (e.g., a paper sheet included in the kit), but machine-readable
instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
The kits described herein are in suitable packaging. Suitable packaging include,
but is not limited to, vials, bottles, jars, flexible packaging (e.g., seled Mylar or plastic bags), and
the like. Kits may optionally provide additional components such as buffers and interpretative
information. The present application thus also provides articles of manufacture, which include
vials (such as sealed vials), bottles, jars, flexible packaging, and the like.
The instructions relating to the use of the nanoparticle compositions generally
include information as to dosage, dosing schedule, and specific instructions on delivering the
nanoparticle composition. The containers may be unit doses, bulk packages (e.g., multi-dose
packages) or sub-unit doses. Kits may also include multiple unit doses of the macrolide and
pharmaceutical compositions and instructions for use and packaged in quantities sufficient for
storage and use in pharmacies, for example, hospital pharmacies and compounding pharmacies.
Those skilled in the art will recognize that several embodiments are possible
within the scope and spirit of this invention. The invention will now be described in greater
detail by reference to the following non-limiting examples. The following examples further
illustrate the invention but, of course, should not be construed as in any way limiting its scope.
EXAMPLES
Example 1. Method for periadventitial injection with micro-infusion catheter
This example demonstrates the injection of Nab-rapamycin into the
periadventitial tissue. Nab-rapamycin (Celgene Corporation) was reconstituted in saline to 5
mg/ml prior to the injection.
To inject Nab-rapamycin into the periadventitial tissue, the Bullfrog® Micro-
Infusion Catheter (Mercator Medsystems, San Leandro CA) was introduced into the artery while
deflated and with the 0.9 mm needle sheathed within a balloon (Figure 1A). When the balloon
was inflated, the needle extruded outward, perpendicular to the axis of the catheter while a
backing balloon provided an opposing force to slide the needle into the artery wall (Figure 1B).
Nab-rapamycin was then delivered into the periadventitial tissue through the needle.
Example 2. Periadventitial delivery of Nab-rapamycin in a porcine femoral artery balloon
injury model
This experiment was conducted to determine whether periadventitial delivery of
Nab-rapamycin can decrease luminal stenosis in a porcine femoral artery balloon angioplasty
injury model.
Sixteen juvenile male Yorkshire cross pigs (average weight 34.9±2.3kg) were
used in 2 study arms (Figure 2). After induction of general anesthesia, percutaneous access was
obtained via the carotid artery. Animals were given intravenous heparin (5000 units). All pigs
were maintained on aspirin 81 mg daily after the procedure. Femoral arteries were flushed with
1 liter lactated Ringer’s solution after sacrifice. Arteries were then harvested (pharmacokinetics
arm) or subsequently perfusion fixed at 120 mmHg for 10 minutes with 10% buffered formalin
before harvest (histopathology arm).
Nab-rapamycin was injected by periadventitial injection. An initial diagnostic
angiogram showed the target femoral artery diameter was 4 mm (Figure 3A). The micro-
infusion catheter was positioned in the mid-femoral artery and the balloon was inflated (Figure
3B). A periadventitial injection of Nab-rapamycin solution with 20% iodinated contrast (IsoVue
370) showed circumferential coverage of the vessel (Figure 3C-3E). Completion angiogram
revealed a patent femoral artery (Figure 3F). There was 100% procedural success with 32
injection sites. Average injection time was 90 seconds (1 ml/min). There were no dissections,
early or late thromboses, hemorrhages or arteriovenous fistulas.
Histomorphometry results after periadventitial injection of Nab-rapamycin in the
femoral artery were analyzed. Femoral arteries treated with periadventitial Nab-rapamycin had
significantly larger lumen cross-sectional areas p=0.01 (ANOVA)(Figure 4A), as well as
significantly larger total vessel cross-sectional areas (Figure 4B), p=0.005 (ANOVA) at 28 days
after treatment. There was a trend toward decreasing percent luminal stenosis with Nab-
rapamycin treatment at 28 days. Femoral arteries treated with periadventitial Nab-rapamycin
(500 μg) had a 42% reduction in luminal stenosis at 28 days (19.5 + 3% vs 11.4 + 0.8%, p=0.01
t-test) (Figure 4C). The average medial fibrosis score at 28 days was significantly less in the
Nab-rapamycin treated arteries compared to control arteries treated with vehicle alone (Figure
4D), p<0.0001 (ANOVA).
Pharmacokinetic results after periadventitial injection of Nab-rapamycin in the
femoral artery were analyzed. Blood (serum) rapamycin levels rose in the first hour after a
single periadventitial injection of Nab-rapamycin at 500 μg, but fell by 1 day and were not
detectable by 28 days (Figure 5A). In the femoral artery and surrounding perivascular tissue, the
rapamycin concentration was over 1500-times the serum concentration at 1 hour. Rapamycin
persisted over 8 days and was not detectable by 28 days (Figure 5B).
Histopathology results after periadventitial injection of Nab-rapamycin in the
femoral artery were analyzed. Representative sections of femoral arteries 28 days after
treatment with vehicle (Figure 6A and 6B) or Nab-rapamycin 500μg (Figure 6C and 6D) were
shown in Figure 6. Nab-rapamycin treatment was associated with significantly reduced medial
fibrosis with similar degrees of internal elastic lamina injury (inset, 100x). Vessels were stained
with H&E (Figure 6A and 6C) and trichrome (Figure 6B and 6D) and imaged at 25x.
Further histomorphometry analyses showed that Nab-rapamycin treatment was
associated with significantly reduced proliferation index (Figure 7A). On the other hand, there
was no difference in endothelialization at 28 days in control and Nab-rapamycin treated femoral
arteries (Figure 7B).
Further pharmacokinetics analyses showed that the proliferation index fell
significantly between 3 and 28 days in balloon-injured arteries treated with 500 µg Nab-
rapamycin, p=0.004 (ANOVA)(Figure 8A). Re-endotheolialization occurred by 8 days (Figure
8B).
Additionally, at 3 days, there were significantly fewer adventitial leukocytes in
arteries treated with periadventitial Nab-rapamycin (Figure 9A). By 28 days, Nab-rapamycin
treated arteries had significantly fewer adventitial vessels (Figure 9B).
The results reported herein demonstrate that periadventitial delivery of Nab-
rapamycin is associated with a transient increase and rapid fall in serum rapamycin levels. At 1
hour after treatment, rapamycin levels in the perivascular tissue were over 1500 times those in
the blood and rapamycin was retained in the perivascular tissue for at least 8 days (Figure 5B).
Balloon injured femoral arteries treated with Nab-rapamycin were significantly larger than
vehicle treated arteries, suggesting less negative remodeling. Furthermore, periadventitial
delivery of Nab-rapamycin leads to significant decrease in medial fibrosis.
Nab-rapamycin treated arteries demonstrated significantly less early (3 day)
adventitial leukocyte infiltration. The Ki-67 proliferation index of Nab-rapamycin treated
arteries was significantly lower at 28 days (Figure 8A).
There was no difference in endothelialization at 28 days in control and Nab-
rapamycin treated femoral arteries, and re-endothelialization to balloon-injured Nab-rapamycin
treated vessels appeared to occur in the first week and appeared to complete by 8 days (Figure
). Nab-rapamycin treatment leads to a significantly lower proliferation and significantly lower
medial fibrosis scores, suggesting a mechanism by which rapamycin may affect remodeling in
balloon-injured femoral arteries.
A decrease in early adventitial leukocyte infiltration and subsequent reduction in
medial fibrosis and Ki-67 proliferation index at 28 days suggests a mechanism by which
periadventitial Nab-rapamycin may have an effect.
Although the foregoing invention has been described in some detail by way of
illustration and example for purposes of clarity of understanding, it is apparent to those skilled in
the art that certain minor changes and modifications will be practiced. Therefore, the description
and examples should not be construed as limiting the scope of the invention.
Claims (31)
1. Use of a composition comprising nanoparticles comprising a macrolide and an albumin in the manufacture of a medicament for treating a disease selected from the group consisting of angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, peripheral artery disease, claudication, and chronic limb ischemia in an individual in need thereof, wherein the medicament is to be injected into a blood vessel wall or tissue surrounding the blood vessel wall in the individual.
2. Use of a composition comprising nanoparticles comprising a macrolide and an albumin in the manufacture of a medicament for treating restenosis in a blood vessel in an individual in need thereof, wherein the medicament is to be injected into the blood vessel wall or tissue surrounding the blood vessel wall.
3. The use of claim 2, wherein the blood vessel is an artery.
4. The use of claim 3, wherein the artery is a coronary artery or a peripheral artery.
5. The use of claim 4, wherein the artery is selected from the group consisting of renal artery, cerebral artery, pulmonary artery, and artery in the leg.
6. The use of claim 5, wherein the artery is pulmonary artery.
7. The use of claim 2, wherein the blood vessel is a vein.
8. The use of any one of claims 1-7, wherein the nanoparticle composition is to be injected into the blood vessel wall.
9. The use of any one of claims 1-7, wherein the nanoparticle composition is to be injected into the tissue surrounding the blood vessel wall.
10. The use of claim 9, wherein the nanoparticle composition is to be injected into the adventitial tissue of the blood vessel.
11. The use of any one of claims 1-10, wherein the nanoparticle composition is to be injected at a dose of about 0.001mg to about 100 mg.
12. The use of claim 11, where the nanoparticle composition is to be injected at a dose of about 0.05 mg to about 5 mg.
13. The use of any one of claims 1-12, wherein the injection volume of the nanoparticle composition is about 0.01ml to about 50ml.
14. The use of claim 13, wherein the injection volume of the nanoparticle composition is about 0.5 ml to about 5ml.
15. The use of any one of claims 1-14, wherein the nanoparticle composition is to be injected though a catheter with a needle.
16. The use of any one of claims 1-15, wherein the nanoparticle composition is to be injected at least once a year.
17. The use of any one of claims 1-16, wherein the nanoparticle composition is to be injected distal or proximal to the disease site.
18. The use of any one of claims 1-16, wherein the nanoparticle composition is to be injected at least about 2 cm away from the disease site.
19. The use of any one of claims 1-16, wherein the nanoparticle composition is to be injected at or adjacent to the disease site.
20. The use of any one of claims 1-19, wherein the macrolide is rapamycin.
21. The use of any one of claims 1-20, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.
22. The use of claim 21, wherein the nanoparticles in the composition have an average diameter of no greater than about 100 nm.
23. The use of claim 22, wherein the nanoparticles in the composition have an average diameter of no less than about 70 nm.
24. The use of any one of claims 1-23, wherein the weight ratio of the albumin and the macrolide in the composition is about 1:1 to about 18:1.
25. The use of claim 24, wherein the weight ratio of the albumin and the macrolide in the composition is about 1:1 to about 9:1.
26. The use of any one of claims 1-25, wherein the macrolide in the nanoparticles are coated with albumin.
27. The use of any one of claims 1-26, wherein the individual is human.
28. The use of any one of claims 1-27, wherein the injection is to be carried out during a vascular interventional procedure.
29. The use of any one of claims 1-27, wherein the injection is to be carried out after a vascular interventional procedure.
30. The use of claims 28 or 29, wherein the interventional procedure is angioplasty, stenting, or atherectomy.
31. A use according to claims 1 or 2, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161518084P | 2011-04-28 | 2011-04-28 | |
US61/518,084 | 2011-04-28 | ||
US201161557851P | 2011-11-09 | 2011-11-09 | |
US61/557,851 | 2011-11-09 | ||
NZ617139A NZ617139B2 (en) | 2011-04-28 | 2012-04-27 | Intravascular delivery of nanoparticle compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ714092A NZ714092A (en) | 2017-07-28 |
NZ714092B2 true NZ714092B2 (en) | 2017-10-31 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200306180A1 (en) | Intravascular delivery of nanoparticle compositions and uses thereof | |
AU2011261684B2 (en) | Methods of treating bladder cancer | |
NZ714092B2 (en) | Intravascular delivery of nanoparticle compositions and uses thereof | |
NZ617139B2 (en) | Intravascular delivery of nanoparticle compositions and uses thereof | |
RU2361615C2 (en) | Compositions and ways of pharmacological agents delivery |